- Home
- LXEO vs TIPT Comparison
LXEO vs TIPT Comparison
Compare LXEO & TIPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | LXEO | TIPT |
|---|---|---|
| Founded | 2017 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Property-Casualty Insurers |
| Sector | | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 731.3M | 653.2M |
| IPO Year | 2023 | 2007 |
Fundamental Metrics
Financial Performance| Metric | LXEO | TIPT |
|---|---|---|
| Price | $6.59 | $17.45 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 10 | 0 |
| Target Price | ★ $18.60 | N/A |
| AVG Volume (30 Days) | ★ 911.2K | 181.3K |
| Earning Date | 03-23-2026 | 02-26-2026 |
| Dividend Yield | N/A | ★ 1.36% |
| EPS Growth | N/A | ★ 17.79 |
| EPS | N/A | ★ 1.15 |
| Revenue | N/A | ★ $2,070,076,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $15.37 |
| Revenue Growth | N/A | ★ 4.25 |
| 52 Week Low | $1.45 | $17.07 |
| 52 Week High | $10.99 | $27.41 |
Technical Indicators
Market Signals| Indicator | LXEO | TIPT |
|---|---|---|
| Relative Strength Index (RSI) | 33.85 | 44.31 |
| Support Level | $6.73 | $17.26 |
| Resistance Level | $7.31 | $17.99 |
| Average True Range (ATR) | 0.46 | 0.38 |
| MACD | -0.00 | 0.02 |
| Stochastic Oscillator | 17.16 | 27.36 |
Price Performance
Historical ComparisonAbout LXEO Lexeo Therapeutics Inc.
Lexeo Therapeutics Inc is a clinical-stage genetic medicines company committed to transforming healthcare by applying pioneering science to fundamentally alter how diseases are treated. The company focuses on preclinical and clinical stage gene therapies, specifically hereditary and acquired diseases with high unmet needs, which represent its sole business segment.
About TIPT Tiptree Inc.
Tiptree Inc is a United States-based company that provides specialty insurance products and related services. It has two reportable segments: Insurance and Mortgage. The company generates the majority of its revenue from the Insurance Segment, which is engaged in designing, marketing, and underwriting specialty property and casualty insurance products incorporating value-added coverages and services for select target markets or niches. The Mortgage segment originates loans for sale to institutional investors, including GSEs and FHA/VA, and services loans on behalf of Fannie Mae, Freddie Mac, and Ginnie Mae.